New Research Points to Need for Standardized Peritoneal Mesothelioma Treatment, According to Surviving Mesothelioma

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

Scientists in Belgium and the US say there are currently too many different ways to deliver intraperitoneal chemotherapy, making it difficult to collect reliable treatment data.

Doctors at two Belgian universities and the Washington Cancer Institute in Washington, DC, are calling for more standardization of the peritoneal mesothelioma treatment that combines cytoreductive surgery and intraperitoneal chemotherapy (HIPEC). Surviving Mesothelioma has a more complete explanation in a new article. Click here to read it now.

The researchers say the problem is that mesothelioma doctors and others treating malignancies on the peritoneal surface do not use a consistent dose, duration or even drug for HIPEC.

“Although there is near universal standardization regarding the cytoreductive surgery, we are still lacking a much-needed standardization amongst the various intraperitoneal chemotherapy treatment modalities used today in clinical practice,” write the three authors, including Paul Sugarbaker, MD, of the Washington Cancer Institute.

According to the article in the International Journal of Hyperthermia, the combination of cytoreductive surgery and HIPEC is now the standard of care for peritoneal mesothelioma. But even among patients who have this treatment, peritoneal mesothelioma survival varies widely from just a few months to many years.

“Until there is more standardization in the way doctors treat peritoneal mesothelioma, it will be impossible to know how effective this treatment combination really is at extending mesothelioma survival,” says Alex Strauss, Managing Editor for Surviving Mesothelioma.

To read the details of the new CRS/HIPEC report, see Standardization Needed for Peritoneal Mesothelioma Treatment, now available on the Surviving Mesothelioma website.

Lemoine, L, et al, “Drugs, doses, and durations of intraperitoneal chemotherapy: standardizing HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma”, Volume 33, 2017, International Journal of Hyperthermia,



Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.